Classifications

• • G—PHYSICS
  • G02—OPTICS
  • G02C—SPECTACLES; SUNGLASSES OR GOGGLES INSOFAR AS THEY HAVE THE SAME FEATURES AS SPECTACLES; CONTACT LENSES
  • G02C7/00—Optical parts
  • G02C7/10—Filters, e.g. for facilitating adaptation of the eyes to the dark; Sunglasses
  • G02C7/108—Colouring materials
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
  • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
  • A61F2/02—Prostheses implantable into the body
  • A61F2/14—Eye parts, e.g. lenses or corneal implants; Artificial eyes
  • A61F2/16—Intraocular lenses
  • A61F2/1613—Intraocular lenses having special lens configurations, e.g. multipart lenses; having particular optical properties, e.g. pseudo-accommodative lenses, lenses having aberration corrections, diffractive lenses, lenses for variably absorbing electromagnetic radiation, lenses having variable focus
  • A61F2/1659—Intraocular lenses having special lens configurations, e.g. multipart lenses; having particular optical properties, e.g. pseudo-accommodative lenses, lenses having aberration corrections, diffractive lenses, lenses for variably absorbing electromagnetic radiation, lenses having variable focus having variable absorption coefficient for electromagnetic radiation, e.g. photochromic lenses

Definitions

• the present invention relates to ophthalmic devices suitable for use in mammals. More specifically, the present invention relates to ophthalmic devices having at least one highly selective (abrupt) violet light transmissive filter incorporated therein. Additionally, related methods for making ophthalmic devices having highly selective violet light transmissive filters are provided.
• the retina is a multi- layered sensory tissue that lines the back of the eye. It contains millions of photoreceptors that capture light rays and convert them into electrical impulses. These impulses travel along the optic nerve to the brain where they are turned into images.
• photoreceptors in the retina rods and cones.
• the retina contains approximately 6 million cones. The cones are contained in the macula, the portion of the retina responsible for central vision. They are most densely packed within the fovea, the very center portion of the macula. Cones function best in bright light and allow us to appreciate color. There are approximately 125 million rods.
• the rods are responsible for peripheral and night vision.
• the retina is essential for vision and is easily damaged by prolonged unprotected exposure to visible and near visible light.
• Light-induced retinal pathologies include cystoid macular oedema, solar retinopathy, ocular melanomas and age-related macular degeneration (ARMD).
• Light-induced retinal damage is classified as structural, thermal or photochemical and is largely determined by the exposure time, power level and wavelength of light (W.T. Ham. 1983. Journal of Occupational Medicine. 25:2 101-102).
• the cornea is a transparent proteinaceous ocular tissue located before the iris and is the only eye structure exposed directly to the environment.
• the cornea is essential for protecting the delicate internal structures from damage and facilities the transmission of light through the aqueous media to the crystalline lens.
• the cornea is the primary light filter and therefore is particularly susceptible to excessive light exposure-related damage including corneo-conjunctival diseases such as pterygium, droplet climatic keratopathy and pinguecula.
• the cornea in conjunction with the aqueous medium, absorbs, or blocks, wavelengths (nm shall be used hereinafter to denote wavelengths of light in nanometers) in the short ultraviolet (UV)-B and UV-C region (less than ⁇ 320 nm).
• the crystalline lens is an accommodating biological lens lying directly behind the iris and cornea and facilitates the convergence of both far and near images onto the retina.
• the natural crystalline lens blocks near UV radiation (UV-A) (320 nm to 400 nm) from reaching the retina. Therefore, most of the damaging UV-A, -B and -C radiation are prevented from reaching the retina in healthy people with an intact crystalline lens and cornea.
• UV-A near UV radiation
• -B and -C radiation are prevented from reaching the retina in healthy people with an intact crystalline lens and cornea.
• UV-A near UV radiation
• -B and -C radiation are prevented from reaching the retina in healthy people with an intact crystalline lens and cornea.
• UV-A near UV radiation
• -B and -C radiation are prevented from reaching the retina in healthy people with an intact crystalline lens and cornea.
• high transmittance levels of blue and violet light has been linked to retinal damage, macular degeneration, retinitis pigmentosa, and night blindness.
• blue and violet light tends to be scattered in the atmosphere, especially in haze, fog, rain, and snow, which in part can cause glare, and diminished visual acuity.
• the crystalline lens begins to take on a yellow tint that absorbs some radiation in the blue and violet wavelength ranges, in addition to the majority of near UV radiation.
• the natural crystalline lens protects the eye's delicate retina from near UV light throughout life and subtly yellows with age, thereby increasing the amount of blue and violet light that is absorbed.
• the natural crystalline lens is also susceptible to age-related degenerative eye diseases such as cataracts.
• Cataract is a clouding of the crystalline lens caused by the coagulation of lens proteins within the capsular sac.
• Many ophthalmologists believe that cataract formation results from a lifetime of oxidative insults to the lens and is exacerbated by smoking, excessive exposure to bight light, obesity and diabetes.
• Cataracts develop slowly in most people and eventually reach the point where vision is substantially impaired resulting in near to total blindness.
• lens removal and replacement with synthetic polymer ophthalmic devices such as an intraocular lens is the preferred means for restoring normal sight.
• synthetic polymer ophthalmic devices such as an intraocular lens is the preferred means for restoring normal sight.
• the retina is left unprotected from damaging UV and short wavelength violet light.
• UV absorbing compounds such as benzophenones and benzotriazoles-based UV light absorbers.
• many benzophenones and benzothazoles are polymerizable and thus can be stably integrated into most modern ophthalmic device compositions including acrylates and hydrophilic hydrogel co-monomers and co-polymers.
• Ultraviolet light does not play a positive role in human vision.
• ophthalmic devices having UV absorbing dye concentrations that block virtually all UV light became common-place by the mid 1980s.
• the violet light-absorbing portion of the molecule is protected from undesirable color shifts when polymerized with the lens polymer.
• the dye is acrylic- functionalized, it is polymerizable with the lens polymer and thus stably incorporated into the ophthalmic device polymer matrix.
• Menicon Co., Ltd. holds USPNs 6,277,940 and 6,326,448 both disclosing specific acrylic-modified azo dyes structurally similar to Alcon's.
• Hoya Corporation owns USPN 5,374,663 that discloses non-covalently linked yellow dyes including solvent yellow numbers 16, 29 and others incorporated into a PMMA matrix.
• Hoya also owns USPN 6,310,215 that discloses acrylic-functionalized pyrazolone dyes suitable for use in acrylic and silicone ophthalmic devices.
• the violet light spectrum (440 nm to about 500 nm) are important for maintaining optimal visual acuity, especially scotopic (night) vision.
• ophthalmic devices containing dyes that block significant amounts of violet light over the majority of the violet light spectrum can adversely affect scotopic vision. This is an especially acute problem in older adults that naturally suffer declining scotopic vision and reduced pupil dilation. Consequently, an ophthalmic device is needed that balances the need for reducing the possible damaging effects of blue and violet light exposure against the need to maintain good scotopic vision.
• the present invention achieves this and other objectives by providing an ophthalmic device having a violet light absorbing dye that selectively filters wavelengths between approximately 400 nm to about 450 nm with little or no absorption of wavelengths above 450 nm (referred to herein after as a "violet-light vertical cut-off filter").
• the ophthalmic devices of the present invention may be composed of any biocompatible polymer suitable for use in forming an ophthalmic device.
• PMMA poly(methylmethacrylate)
• Additional polymers may be used when made using monomers selected from the non-limiting group consisting of phenylethylacrylate (PEA), phenylethylmethacrylate (PEMA), methylphenylacrylates, methylphenylmethacrylates, 2-hydroxyethyl methacrylate (HEMA).
• heterocyclic N-vinyl compounds containing a carbohyl functionality adjacent to the nitrogen in the ring, and particular N-vinyl lactams such as N-vinyl pryrolidone are also suitable for use in accordance with the teachings of the present invention.
• the ophthalmic devices of the present invention may also be cross-linked using di- or multi-functional monomers and in small amounts as is well known in the art.
• Representative crosslinking agents include ethylene glycol dimethacrylate, triethylene, glycol dimethacrylate and trimethylolpropane trimethacrylate.
• the cross linking agents are typically dimethacrylates or diacrylates, although dimethacrylamides are also known.
• the light absorbing dye used to form the violet-light vertical cut-off filter may be any dye capable of absorbing light between approximately 400 nm to about 450 nm.
• Exemplary light absorbing dyes include, but not limited to, dyes available from Eastman Chemical such as, but not limited to, Eastman Yellow 035-MA. This dye is a methine class dye and is easily provided with a polymerizable methacrylate group.
• the absorption spectrum for Yellow 035-MA is provided in Figure 3.
• This dye is particularly beneficial because it is a reactive dye that can be chemically bonded to the ophthalmic device polymer so that the lens is colorfast and the dye is non-extractable (i.e. will not bleed or leach out of the lens).
• other dyes may also be used in accordance with the teachings of the present invention capable of absorbing the desired wavelength of light.
• lenses having additional light absorbing dyes specifically dyes that absorb light in the ultraviolet region, for example, but not limited to benzophenones and benzotriazoles.
• the ophthalmic device is a filter only and does not itself have any significant optical power.
• an ophthalmic device is a lens suitable for implantation into the eye of a mammal such as an intraocular lens or corneal implant wherein the lens comprises a violet-light vertical cut-off filter, and wherein the violet- light vertical cut-off filter may be distributed throughout substantially the entire ophthalmic device or may be distributed through less than the entire ophthalmic device (see Figure 6).
• the ophthalmic device has a defined region that comprises at least one light absorbing dye, specifically dyes that absorb visible light in the wavelengths between approximately 400 nm and 450 nm.
• the ophthalmic devices made in accordance with the teachings of the present invention include, without limitation, intraocular lenses, corneal implants, sun glasses, spectacles and contact lenses.
• the present invention provides an ophthalmic device that affords enhanced retina protection in high intensity lighting conditions when protection is needed most, while permitting a fuller spectrum of light to reach the retina in subdued, or low light conditions thus enhancing visual acuity and color perception.
• Figure 1 graphically compares the visible light transmittance curves of an aging natural crystalline lens with a lens containing UV absorbing dyes only (UV-IOL) and a lens containing UV absorbing dyes and conventional violet light absorbing dyes (Alcon Natural).
• UV-IOL UV absorbing dyes only
• Alcon Natural conventional violet light absorbing dyes
• the target filter area for a vertical violet . light cut-off filter made in accordance with the teachings of the present invention is depicted in the shaded box.
• Figure 2 graphically depicts visible light transmittance curves of an ophthalmic device containing dye filters within the target filter area depicted in Figure 1.
• Figure 3 graphically depicts absorption spectrum for Yellow 035-MA in accordance with the teachings of the present invention.
• Figure 4 graphically depicts the idealized filter range (area between the 0.1% and 0.6% curves) for the violet light vertical cut-off filter made in accordance with the teachings of the present invention compared to the state-of-the-art ophthalmic device (Alcon Natural).
• Figure 5 graphically depicts relative phototoxicity versus wavelength in nm and relative luminous (scotopic versus photopic) efficiency as a function of wavelength in nm.
• Figure 6 depicts an embodiment of the present invention wherein the dye used to form the vertical violet light cut-off filter is localized to a core within a composite button that comprises the ophthalmic device
• Figure 7 graphically depicts the violet light vertical cut-off filter made in accordance with the teachings of the present invention as applied to relative phototoxicity as a function of light wavelength overlaid against the scotopic vision curve.
• Figure 7 is essentially a composite of Figure 2 and Figure 5.
• Violet-light vertical cut-off filter shall mean a light absorbing composition that abruptly absorbs light between the wave lengths of between approximately and 400 nm and 450 nm (see Figure 2).
• “abruptly means that the resulting absorption curve (when plotted in percent transmittance versus wavelength in nm) is nearly vertical having the overall shape as depicted in the Figures 2 (within the shaded box) and 4 (the 0.1% and 0.6% curves).
• optical device(s) include without limitation intraocular lenses, sun glasses, spectacles and contact lenses.
• the present invention comprises ophthalmic devices having a violet-light vertical cut-off filter incorporated therein wherein the violet-light vertical cut-off filter abruptly absorbs light between the wavelengths of approximately and 400 nm and 450 nm (see Figure 2).
• the light absorbing dye used to form the violet-light vertical cut-off filter can be any dye capable of absorbing light of predetermined wavelengths within the visible light spectrum.
• the dye used in accordance with the teachings of the present invention absorbs light abruptly over a relatively narrow wavelength range. In one embodiment of the present invention the wavelength range is between approximately 400 nm and 450 nm.
• Figure 3 graphically depicts a non-limiting example of an absorption spectrum for one dye used in accordance with the teachings of the present invention.
• Suitable dyes are preferably biocompatible, non-polar, thermally, photochemically and hydrolytically stable.
• the dye also preferably has have a narrow absorption bandwidth such that it acts as a substantially vertical filter.
• the full width at half maximum (FWHM) bandwidth is less than 100 nm, in a preferred embodiment the absorption band width is less than 75 nm and in an even more preferred embodiment the FWHM bandwidth is less than 50 nm.
• the dyes used in accordance with the teachings of the present invention are capable of being functionalized to allow for polymerization with the structural polymers of the lens.
• the dye is acrylate functionalized. This is particularly beneficial because functionalized dyes can be chemically bonded to the ophthalmic device polymer so that the lens is colorfast and the dye is non-extractable (i.e. will not bleed or leach out of the lens). However, it is not essential that the dye be polymerizable or capable of bonding to the ophthalmic device polymer.
• the dye is an Eastman Chemical yellow dye designated as Eastman Yellow 035-MA.
• the empirical formula of this dye is C 20 H 25 N 3 O5S and its structure is shown below as structure 1.
• This dye is a methine dye having the absorption spectrum depicted in Figure 3.
• the dye is functionalized with methacrylate groups and is present in the finished ophthalmic device at a concentration of between approximately 0.005% to 0.2% (w/w), preferably between approximately 0.01 % to 0.1% (w/w); the structural polymer, UV absorbing dye, solvents and other biocompatible excipients making up the remaining lens composition.
• the ophthalmic devices according to the present invention may be made from biocompatible polymers and include, without limitation, poly(methylmethacrylate) (PMMA). Additional polymers may be used when made using monomers selected from the non- limiting group consisting of phenylethylacrylate (PEA), phenylethylmethacrylate (PEMA), methylphenylacrylates, methylphenylmethacrylates, 2-hydroxyethyl methacrylate (HEMA). Moreover, heterocyclic N-vinyl compounds containing carbonyl functionality adjacent to the nitrogen in the ring, and particular N-vinyl lactams such as N-vinyl pryrolidone are also suitable for use in accordance with the teachings of the present invention.
• PMMA poly(methylmethacrylate)
• Additional polymers may be used when made using monomers selected from the non- limiting group consisting of phenylethylacrylate (PEA), phenylethylmethacrylate (PEMA), methylphen
• the ophthalmic devices of the present invention may also be cross-linked using di- or multifunctional monomers and in small amounts as is well known in the art.
• Representative crosslinking agents include ethylene glycol dimethacrylate, triethylene, glycol dimethacrylate and trimethylolpropane trimethacrylate.
• the crosslinking agents are typically dimethacrylates or diacrylates, although dimethacrylamides are also known.
• Additional suitable lens-forming monomers for use in the present invention include listed at column 7, line 63 through column 8 line 40 of USPN 5,662,707, the contents of which is herein incorporated by reference. See also USPN 5,269,813 column 2 line 14 through column 7 line 52, specifically Table 1 , this US patent is also incorporated by reference both in its entirety and as specifically cited.
• the ophthalmic devices of the present invention may also contain at least one near-ultraviolet (UV) light absorbing compound such as benzophenones and benzotriazoles.
• UV light absorbing compound such as benzophenones and benzotriazoles.
• Suitable examples can be found in USPNs 4,716,234 (specifically see column 3 line 67 through column 10 line 24); 4,963,160 (specifically column 2 line 61 through column 4 line 19); 5,657,726 (specifically column 2 line 36 through column 4 line 67) and 6,244,707 (specifically column 3 line 50 through column 6 line 37) the entire contents of which, specifically the cited columns numbers and lines, are herein incorporated by reference.
• the ophthalmic devices of the present invention reduce the impact on scotopic vision by substantially not blocking light above 500 nm, absorbing primarily violet and ultraviolet light.
• the ophthalmic devices also provides retinal protection, by blocking all UV light and selectively filter some blue and violet light up to approximately 450 nm.
• Figure 1 compares the naturally aging human crystalline lens (the black line) with a state-of-the-art ophthalmic device containing a violet light blocking dye (an Azo-class dye) (Alcon Natural) demonstrating a significant drop in light transmittance for light in the blue wavelength range (between about 440 nm and 500 nm).
• the UV-IOL line depicts an ophthalmic device containing UV absorbing dyes but no violet-light absorbing dyes. Note that both the commercial ophthalmic device and the natural human lens show a significant drop in transmittance between 400 nm and 550 nm as compared to the ophthalmic device lacking a violet blocking dye.
• FIG. 5 graphically depicts the non-limiting theory behind the present invention.
• Curve A ⁇ depicts retinal damage as a function of wavelength.
• the retinal damage potential phototoxicity
• Curve V depicts relative luminous efficiency for scotopic vision.
• scotopic vision luminous efficiency peaks at approximately 515 nm.
• Curve demonstrates that photopic vision peaks at approximately 550 nm.
• the area depicted in the shaded box in Figure 5 represents a preferred ideal wavelength range (approximately 400 nm to 450 nm) for the violet-light vertical cut-off filter of the present invention.
• the violet-light vertical cut-off filter region of the present invention depicted in Figure 5 reduces blue/violet light-induced phototoxicity while also reducing interference with violet light wavelengths essential for optimum scotopic vision.
• an ophthalmic device having at least one light absorbing dye used to form a violet light vertical cut-off filter according to the present invention is preferably restricted to the wavelengths as depicted in Figure 2 and would strike a compromise between retinal protection and scotopic vision. It is understood that such an ideal ophthalmic device would also contain UV absorbing dyes that would prevent UV-induced phototoxicity as well.
• Figure 7 (Figure 7 is essentially a composite of Figures 2 and 5) demonstrates two aspects of the present invention.
• curve gradients slopes
• Figure 7 demonstrates that wavelength absorption curve gradient should be relatively independent of dye concentration.
• changes in dye concentration can slightly effect wavelength spread (compare the origins of 0.1% dye mass to the 0.6% dye mass along the X-axis). This is especially important because conventional ophthalmic devices have the dye dispersed uniformly throughout the structural polymer.
• lens thickness is modified to change diopter, dye concentration changes. Consequently, if the curve gradient were excessively dye-concentration dependent, scoptoic vision and retinal protection characteristics of the ophthalmic device would vary significantly with diopter.
• Figure 2 demonstrates that a ten-fold change in dye concentration, when used in accordance with the teachings of the present invention, only slightly shifts the wavelength absorption spread and has virtually no impact on curve gradient.
• Figure 4 illustrates that for a fixed diopter (20D) lens, a six-fold increase in dye concentration change results in a consistent curve gradient and relatively little shift in wavelength absorption characteristics.
• the steepness of the curve gradient remains constant and thus acts as a vertical cut-off filter in accordance with the teachings herein.
• the dye concentration remains constant regardless of lens thickness, and hence diopter, by localizing the dye with is a central core.
• the lens design in Figure 6 has the added advantage of localizing the dye to the pupil area of the lens.
• the constricted pupil is completely within the dye containing zone of the ophthalmic device.
• the dilated pupil receives both filtered and unfiltered light. This is discussed more fully in U.S. utility application serial number 11/027,876.
• ophthalmic devices having at least one violet light absorbing dye with an absorption profile essentially the same as that depicted in Figure 3.
• the violet light absorbing dyes are generally biocompatible, non-polar and capable of being functionalized such that they can be polymerized with the ophthalmic device structural polymers.
• violet- light absorbing dyes having a methine linkage are used. Light absorbing dyes having methine linkages are described in U.S. patent number 5,376,650 issued December 27, 1994 the entire contents of which is herein incorporated by reference in its entirety.
• the dye is an Eastman Chemical yellow dye designated as Eastman Yellow 035-MA.
• This dye is a methine dye having the absorption spectrum depicted in Figure 3.
• the dye is functionalized with methacrylate groups and is present in the finished ophthalmic device at a concentration of between approximately 0.005% to 0.2% (w/w), preferably between approximately 0.01% to 0.1% (w/w); the structural polymer, UV absorbing dye, solvents making and other biocompatible excipients making up the remaining lens composition.
• the ophthalmic devices made in accordance with the teachings of the present invention have a violet-light vertical cut-off filter incorporated therein wherein the violet-light vertical cut-off filter abruptly absorbs light between the wavelengths of between approximately 400 nm and 450 nm (see Figure 2).
• the wavelength spread and curve gradient, or slope is within the parameters depicted in Figures 2 and 5 as depicted in the shaded box. However, it is understood that the wavelength absorption range can extend to 400 nm at the low end and 450 nm at the high end providing the curve gradient remains as depicted in Figure 2.
• an ophthalmic device having a violet-light vertical cut-off filter as described above wherein the ophthalmic device has the structural characteristics depicted in Figure 6.
• the violet light absorbing dye may or may not be functionalized and may or may not be co-polymerized with the structural polymer.

Landscapes

• Health & Medical Sciences (AREA)
• Ophthalmology & Optometry (AREA)
• Physics & Mathematics (AREA)
• General Health & Medical Sciences (AREA)
• Engineering & Computer Science (AREA)
• Vascular Medicine (AREA)
• Electromagnetism (AREA)
• Cardiology (AREA)
• Oral & Maxillofacial Surgery (AREA)
• Transplantation (AREA)
• General Physics & Mathematics (AREA)
• Biomedical Technology (AREA)
• Heart & Thoracic Surgery (AREA)
• Optics & Photonics (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Eyeglasses (AREA)
• Prostheses (AREA)
• Materials For Medical Uses (AREA)
• Optical Filters (AREA)

Priority Applications (6)

Applications Claiming Priority (2)

Publications (1)

Family

ID=34967496

Family Applications (1)

Country Status (7)

Cited By (11)

Families Citing this family (84)

Citations (6)

Family Cites Families (90)

• 2005
  • 2005-04-26 US US11/115,743 patent/US7278737B2/en not_active Expired - Lifetime
  • 2005-04-26 CA CA2564921A patent/CA2564921C/en not_active Expired - Lifetime
  • 2005-04-26 JP JP2007510936A patent/JP2007535708A/ja active Pending
  • 2005-04-26 AU AU2005242823A patent/AU2005242823B2/en not_active Expired
  • 2005-04-26 EP EP12193169.5A patent/EP2574976B1/en not_active Expired - Lifetime
  • 2005-04-26 EP EP05740969A patent/EP1740999A1/en not_active Withdrawn
  • 2005-04-26 BR BRPI0509338-4A patent/BRPI0509338B1/pt active IP Right Grant
  • 2005-04-26 WO PCT/US2005/014465 patent/WO2005111702A1/en not_active Ceased
• 2007
  • 2007-09-07 US US11/851,560 patent/US20080013045A1/en not_active Abandoned
• 2009
  • 2009-12-10 US US12/635,489 patent/US8047650B2/en not_active Expired - Lifetime
• 2011
  • 2011-09-23 US US13/243,455 patent/US8292428B2/en not_active Expired - Lifetime
  • 2011-11-04 JP JP2011242597A patent/JP5395149B2/ja not_active Expired - Lifetime

Patent Citations (6)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events